Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Kenneth C. Rupert; James R. Henry; John H. Dodd; Scott A. Wadsworth; Druie E. Cavender; Gilbert C. Olini; Bohumila Fahmy; John J. Siekierka

doi:10.1016/S0960-894X(02)01020-X

Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Kenneth C. Rupert
, James R. Henry
, John H. Dodd
, Scott A. Wadsworth
, Druie E. Cavender
, Gilbert C. Olini
, Bohumila Fahmy
, John J. Siekierka

Chemistry

Research output: Contribution to journal › Article › peer-review

291 Scopus citations

Abstract

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

Original language	English (US)
Pages (from-to)	347-350
Number of pages	4
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	13
Issue number	3
DOIs	https://doi.org/10.1016/S0960-894X(02)01020-X
State	Published - Feb 2003

All Science Journal Classification (ASJC) codes

Biochemistry
Molecular Medicine
Molecular Biology
Pharmaceutical Science
Drug Discovery
Clinical Biochemistry
Organic Chemistry

Access to Document

10.1016/S0960-894X(02)01020-X

Cite this

@article{b208462ab5a744a29ab597039fb901cf,

title = "Imidazopyrimidines, potent inhibitors of p38 MAP kinase",

abstract = "The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.",

author = "Rupert, \{Kenneth C.\} and Henry, \{James R.\} and Dodd, \{John H.\} and Wadsworth, \{Scott A.\} and Cavender, \{Druie E.\} and Olini, \{Gilbert C.\} and Bohumila Fahmy and Siekierka, \{John J.\}",

year = "2003",

month = feb,

doi = "10.1016/S0960-894X(02)01020-X",

language = "English (US)",

volume = "13",

pages = "347--350",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Ltd",

number = "3",

}

TY - JOUR

T1 - Imidazopyrimidines, potent inhibitors of p38 MAP kinase

AU - Rupert, Kenneth C.

AU - Henry, James R.

AU - Dodd, John H.

AU - Wadsworth, Scott A.

AU - Cavender, Druie E.

AU - Olini, Gilbert C.

AU - Fahmy, Bohumila

AU - Siekierka, John J.

PY - 2003/2

Y1 - 2003/2

N2 - The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

AB - The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

UR - https://www.scopus.com/pages/publications/0037330356

UR - https://www.scopus.com/pages/publications/0037330356#tab=citedBy

U2 - 10.1016/S0960-894X(02)01020-X

DO - 10.1016/S0960-894X(02)01020-X

M3 - Article

C2 - 12565927

AN - SCOPUS:0037330356

SN - 0960-894X

VL - 13

SP - 347

EP - 350

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

IS - 3

ER -

Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this